Xenon Pharmaceuticals (XENE) Return on Capital Employed (2014 - 2026)

Xenon Pharmaceuticals (XENE) has 13 years of Return on Capital Employed data on file, last reported at 42.53% in Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 287.0% year-over-year to 42.53% in Q1 2026; TTM through Mar 2026 was 42.53%, a 287.0% decrease from a year earlier, with the FY2025 full-year figure at 55.36%, down 2234.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 42.53%, up from 64.47% in the prior quarter.
• Over the last five years, Return on Capital Employed for XENE reached as high as 13.17% in Q2 2022 and fell as low as 64.47% in Q4 2025.
• Historically, Return on Capital Employed has averaged 31.53% across 5 years, with a median of 27.61% in 2023.
• Across the five-year window, Return on Capital Employed jumped 1188 bps in 2022 and tumbled 2872 bps in 2025, its largest moves.
• Year by year, Return on Capital Employed stood at 17.4% in 2022, then plunged by 56 bps to 27.07% in 2023, then slumped by 32 bps to 35.74% in 2024, then slumped by 80 bps to 64.47% in 2025, then jumped by 34 bps to 42.53% in 2026.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 42.53% in Q1 2026, 64.47% in Q4 2025, and 56.54% in Q3 2025.